The American Journal of Medicine
Volume 122, Issue 2 , Pages 114-120 , February 2009

From Randomized Controlled Trials to Observational Studies

  • Stuart L. Silverman, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Stuart L. Silverman, MD, Clinical Professor of Medicine, Cedars-Sinai Medical Center, David Geffen School of Medicine UCLA, OMC Clinical Research Center, 8641 Wilshire Blvd. Suite 301, Beverly Hills, CA 90211

References 

  1. Dowd R, Recker RR, Heaney RP. Study subjects and ordinary patients. Osteoporos Int. 2000;11:533–536
  2. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312:1215–1218
  3. Ayanian JZ. Using administrative data to assess health care outcomes. Eur Heart J. 1999;20:1689–1691
  4. Strom BL, Melmon KL. The use of pharmacoepidemiology to study beneficial drug effects. In:  Strom BL editors. Pharmacoepidemiology. 3rd edition. Chichester, UK: John Wiley & Sons, Ltd; 2000;p. 553–572
  5. McKee M, Britton A, Black NM, et al. Methods in health services research (Interpreting the evidence: choosing between randomised and non-randomised studies). BMJ. 1999;319:312–315
  6. Goldberg RJ, Dalen JE. Enhancing peer review of scientific manuscripts. Arch Intern Med. 1997;157:380–382
  7. Khan AY, Preskorn SH, Baker B. Effect of study criteria on recruitment and generalizability of the results. J Clin Psychopharmacol. 2005;25:271–275
  8. Zimmerman M, Chelminski I, Posternak MA. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry. 2005;162:1370–1372
  9. Motheral BR, Fairman KA. The use of claims databases for outcomes research: rationale, challenges, and strategies. Clin Ther. 1997;19:346–366
  10. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296:2563–2571
  11. Gold DT, McClung B. Approaches to patient education: emphasizing the long-term value of compliance and persistence. Am J Med. 2006;119(4 Suppl 1):S32–S37
  12. Ioannidis JA, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285:437–443
  13. Hess DR. Retrospective studies and chart reviews. Respir Care. 2004;49:1171–1174
  14. Dawson B, Trapp RG. Basic & Clinic Biostatistics. 3rd edition. New York: The McGraw-Hill Companies, Inc; 2001;7-23
  15. Miller PD, Silverman SL, Gold DT, et al. Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) Study. Osteoporos Int. 2006;17:85–90
  16. Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies – report of the ISPOR Task Force on Retrospective Databases. Value Health. 2003;6:90–97
  17. Lindsay R. Beyond clinical trials: the importance of large databases in evaluating differences in the effectiveness of bisphosphonate therapy in postmenopausal osteoporosis. Bone. 2007;40:S32–S35
  18. Hlatky MA, Lee KL, Harrell FE, et al. Tying clinical research to patient care by use of an observational database. Stat Med. 1984;3:375–387
  19. Van Staa TP, Geusens P, Leufkens HGM, Cooper C. Persistence to bisphosphonate treatment in actual clinical practice. European Calcified Tissue Society meeting, June 25-29, 2005, Geneva, Switzerland [abstract P610-Su].
  20. Papanikolaou PN, Christidi GD, Ioannidis JP. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ. 2006;174:635–641
  21. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol. 2006;97(Suppl 8A):61C–68C
  22. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878–1886
  23. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887–1892
  24. Ioannidis JPA, Hiadich AB, Pappa M, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA. 2001;286:821–830
  25. Watts NB, Worley K, Solis A, et al. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm. 2004;10:142–151
  26. Black DM, Thompson DE, Bauer DC, et al. FIT Research Group Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab. 2000;85:4118–4124
  27. Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;74:129–135
  28. Wei L, Ebrahim S, Bartlett C, et al. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ. 2005;330:821
  29. Hartz A, Bentler S, Charlton M, et al. Assessing observational studies of medical treatments. Emerg Themes Epidemiol. 2005;2:8
  30. Lobo FS, Wagner S, Gross CR, Schommer JC. Addressing the issue of channeling bias in observational studies with propensity scores analysis. Res Social Adm Pharm. 2006;2:143–151
  31. Silverman SL, Watts NB, Delmas PD, et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int. 2007;18:25–34
  32. Ray WA, Griffin MR, Fought RL, Adams ML. Identification of fractures from computerized Medicare files. J Clin Epidemiol. 1992;45:703–714
  33. Curtis JR, Westfall AO, Allison J, et al. Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepidemiol Drug Saf. 2006;15:710–718

 Funding: The author received editorial support in the preparation of this manuscript funded by The Alliance for Better Bone Health (Procter & Gamble Pharmaceuticals and sanofi-aventis U.S., Inc). The author, however, was fully responsible for all content and editorial decisions and received no financial support or other form of compensation related to the development of the article.

 Conflict of interest: The author is a consultant and speaker for The Alliance for Better Bone Health and has received research grant support.

 Authorship: The author had access to the data and maintained complete control of manuscript development.

PII: S0002-9343(08)00952-2

doi: 10.1016/j.amjmed.2008.09.030

The American Journal of Medicine
Volume 122, Issue 2 , Pages 114-120 , February 2009

Article Tools

* Image Usage & Resolution